Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

Fig. 1

Enzastaurin inhibited proliferation of ABC and GCB cell lines and up-regulated phosphorylation of BTK. a ABC (HBL-1, TMD8, U2932, SU-DHL-2, OCL-LY10) and GCB (SU-DHL-6, SU-DHL-16, OCI-LY7, OCI-LY8) lymphoma cell lines were cultured with DMSO or enzastaurin with increasing doses up to 20 μM for 72 h. The cell viability was measured by Cell Titer-Glo luminescent cell viability assay. Each cell line was analyzed in triplicate, and data are shown as mean ± SD. b Western blot analysis of p-BTK levels in HBL-1and TMD8 cells after DMSO or enzastaurin treatment for 2 h. c BCR signaling representation. Enzastaurin and ibrutinib block some effectors downstream of the BCR

Back to article page